GLP-1 receptor agonists, such as semaglutide, reduce hepatic fat deposition and improve insulin resistance, with studies demonstrating benefits for liver fat content and inflammatory markers in MASLD patients, though further research is needed to confirm long-term efficacy and antifibrotic effects (61). This evidence concerns the gene GLP1R and Insulin resistance.